New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion

Partnership aims to bring 2 to 4 new antibiotics to patients by the end of the decade and facilitate needed long-term policy solutions

9 July 2020, Geneva — Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund [], a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resistant bacteria and life-threatening infections. Through the AMR Action Fund, pharmaceutical companies will join forces with philanthropies, development banks, and multilateral organizations to strengthen and accelerate antibiotic development. The Fund will focus on urgent public health needs. It will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients.

Please click here to read the full news release

Below are documents pertaining to the AMR Action Fund

The AMR Action Fund – Message House – This document was developed for internal audiences to be used as a starting point for communications related to the AMR Action Fund.

AMR Action Fund – Frequently Asked Questions (FAQ)

AMR Fund Fact Sheet

Save the date – Berlin Launch AMR new initiative 9 July

Media Save the date – AMR new initiative BERLIN launch 9 July